key: cord-0944009-5fgsy1jc
authors: Raja, Mohammed A.; Mendoza, Maria A.; Villavicencio, Aasith; Anjan, Shweta; Reynolds, John M.; Kittipibul, Veraprapas; Fernandez, Anmary; Guerra, Giselle; Camargo, Jose F.; Simkins, Jacques; Morris, Michele I.; Abbo, Lilian A.; Natori, Yoichiro
title: COVID-19 in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis of Current Literature
date: 2020-11-14
journal: Transplant Rev (Orlando)
DOI: 10.1016/j.trre.2020.100588
sha: b23d21ce9e8861805e0266c50c92e830cf1260ff
doc_id: 944009
cord_uid: 5fgsy1jc

Severe acute respiratory virus syndrome 2 (SARS-CoV-2) has led to a worldwide pandemic. Early studies in solid organ transplant (SOT) recipients suggested a wide variety of presentations, however, there remains a paucity of robust data in this population. We conducted a systematic review and meta-analysis of SOT recipients with SARS-CoV-2 infection from January 1(st) t October 9(th), 2020. Pooled incidence of symptoms, treatments and outcomes were assessed. Two hundred and fifteen studies were included for systematic review and 60 for meta-analysis. We identified 2,772 unique SOT recipients including 1,500 kidney, 505 liver, 141 heart and 97 lung. Most common presenting symptoms were fever and cough in 70.2% and 63.8% respectively. Majority (81%) required hospital admission. Immunosuppressive medications, especially antimetabolites, were decreased in 76.2%. Hydroxychloroquine and interleukin six antagonists were administered in59.5% and 14.9% respectively, while only few patients received remdesivir and convalescent plasma. Intensive care unit admission was 29% from amongst hospitalized patients. Only few studies reported secondary infections. Overall mortality was 18.6%. Our analysis shows a high incidence of hospital admission in SOT recipients with SARS-CoV-2 infection. As management of SARS-CoV-2 continues to evolve, long-term outcomes among SOT recipients should be assessed in future studies.

63.8% (95% CI, 55.0%-72.6%, REM, I 2 94.4%) and 30.4% (95% CI, 23.6%-37.2%, REM, I 2 85.4%), respectively (Figure 2A -D) [16, 18, 20, 22, 24, 31, 38, 40, 43, 51, 55, 56, 59, 60, 65, 69, 70, 79, 81, 85, 88, 96, 100, 102, 108, 117, 133, 136, 141-143, 149, 151, 152, 156, 158, 162, 166, 179, 185, 189, 190, 192, 210, 212, 216, 217, 219, 228, 229, 231] 

We then analyzed laboratory results at and after diagnosis of COVID-19. Leukopenia (white blood cell count <4000/mm 3 ) was noted in 19 studies with pooled incidence of 17.8% (95% CI 10.7%-24.8%, REM, I 2 57.2%) [24, 31, 40, 51, 88, 96, 108, 133, 135, 143, 151, 152, 158, 162, 166, 216, 217, 219, 229] . Creactive protein (CRP) level was documented in 161 studies [8, 14, 16-19, 21, 23-25, 31-38, 40, 42-48, 50-52, 55, 56, 59, 60, 62, 63, 66-69, 71-73, 76-82, 84-89, 92-98, 100-104, 106, 108-110, 112, 115, 116, 118-121, 124-130, 133-139, 141, 143, 146, 147, 151-156, 158, 159, 161-167, 169, 171, 174, 177-179, 185, 187-192, 194, 196-200, 203, 204, 206, 207, 210-214, 216, 218-221, 224-226, 228-232, 234-240] . Radiological abnormalities on chest imaging, either radiography or computerized tomography, was found in 28 studies with pooled incidence of 79.7% (95% CI 69.5%-89.9%, REM, I 2 96.0%) [22, 31, 59, 65, 79, 81, 85, 96, 102, 114, 117, 133, 143, 152, 156, 158, 166, 179, 189, 190, 192, 210, 212, 216, 217, 219, 229, 231] (Figure 3 ).

We also analyzed the different treatment modalities used in SOT patients with COVID 19 and findings are summarized in table 2 [18, 20, 22, 24, 31, 55, 59, 60, 65, 70, 79, 81, 85, 88, 96, 102, 108, 114, 117, 133, 136, 142, 143, 151, 156, 158, 166, 179, 183, 189, 192, 210, 212, 216, 219, 231] . Immunosuppressive medications, especially antimetabolites, were decreased in 76.2% (95% CI, 68.4%-84.1%, REM, I 2 91 .9% J o u r n a l P r e -p r o o f , Figure 4A ) [18, 21, 22, 55, 59, 79, 85, 88, 108, 114, 117, 133, 135, 143, 151, 156, 166, 179, 183, 189, 190, 192, 212, 216, 217, 229, 231] . On the other hand, reduction in CNI highly varied from 0%-100% with pooled incidence of 38.7% (95% CI, 29.0%-48.4%, REM, I 2 93.0, Figure 4B ) [16, 18, 21, 23, 24, 38, 40, 51, 55, 69, 81, 85, 88, 100, 114, 117, 128, 133, 136, 143, 151, 166, 179, 183, 189, 212, 216, 217, 228, 229, 231] . Corticosteroids were very seldom reduced in 1.7% (95% CI, 0.1%-3.5%, FEM, I 2 0.0%, Figure   4C ) [18, 21, 51, 59, 69, 88, 100, 114, 128, 133, 151, 166, 192, 212, 216, 217, 229] .

Majority of cases were treated with hydroxychloroquine (59.5% 95% CI, 45.0%-74.0%, REM, I 2 98.7%, supplemental Figure A) [18, 20, 22, 31, 55, 59, 60, 65, 70, 81, 85, 88, 96, 102, 108, 114, 117, 133, 143, 151, 158, 166, 183, 189, 190, 192, 210, 212, 216, 219] . Forty eight percent of cases were also placed on azithromycin (95%CI, 35.2%-62.0%, REM, I 2 97.4%, supplemental Figure B ) [18, 20, 22, 55, 59, 60, 65, 70, 88, 96, 102, 114, 158, 166, 179, 183, 189, 190, 210, 216, 219] . Interleukin Six (IL-6) antagonists were used in 14.9% (95% CI, 9.9%-19.9%, REM, I 2 86.7% supplemental Figure C) [18, 20, 22, 55, 60, 70, 79, 85, 88, 117, 133, 136, 189, 192, 210] . Protease inhibitors were used in 28.8% (95% CI, 19.1%-38.5%, REM, I 2 82.8% supplemental Figure D) [20, 24, 31, 56, 70, 108, 143, 151, 189, 210, 212] . Use of high dose steroids, [defined as prednisone at least 1mg/kg, hydrocortisone at least 100mg/day, methylprednisolone at least 200mg/daily, dexamethasone (>2mg/day)], was reported in 19 studies with a pooled incidence of 38.9% (95% CI, 27.9%-49.8%, REM, I 2 97.0% ,supplemental Figure E) [18, 20, 22, 55, 60, 70, 81, 108, 117, 133, 142, 156, 158, 179, 183, 189, 192, 210, 231] . Concurrent antibiotic use was seen in 69.4% (95% CI, 58.9%-79.9%, REM, I 2 94.9%) [16, 24, 32, 40, 50, 51, 55, 60, 79, 81, 102, 108, 136, 151, 162, 166, 179, 185, 190, 199, 210, 212, 216, 219, 229] .

Fourteen studies, excluding potential duplicates, documented use of remdesivir with a total of 36 unique patients [18, 22, 50, 69, 70, 114, 127, 133, 136, 165, 183, 217, 228, 240] , of which 9 studies documented mortality with 2 deaths amongst 14 patients [50, 69, 114, 127, 133, 136, 165, 217, 228] . Thirteen studies, excluding potential duplicates, mentioned use of convalescent plasma with a total of 33 unique patients [24, 33, 46, 69, 90, 110, 114, 133, 136, 165, 185, 199, 228] , of which 11 studies documented about J o u r n a l P r e -p r o o f mortality with a total of 4 deaths from among 31 patients [24, 33, 46, 69, 90, 110, 114, 133, 165, 185, 228] .

Finally, we analyzed outcomes in SOT recipients post COVID-19 infection.

Twenty two studies showed 81.0% pooled incidence of hospital admission (95% CI 75.2%-86.7%, REM, [18, 20, 22, 55, 60, 65, 70, 79, 81, 85, 88, 96, 102, 108, 114, 136, 141, 156, 166, 190, 212, 216] , while 30 studies showed a 29.3% pooled incidence (95% CI 22.6%-36.1%, REM, I 2 89.2%) of admission to the ICU from amongst hospital admissions [18, 20, 22, 31, 59, 60, 70, 79, 81, 85, 88, 96, 102, 108, 114, 117, 133, 143, 151, 152, 158, 166, 179, 183, 189, 190, 210, 212, 216, 229] . Overall, 25.9% of patients required mechanical ventilation (95% CI 20.1%-31.8%, REM, I 2 74.4%) from among hospital admissions [18, 20, 22, 31, 59, 60, 65, 70, 79, 81, 85, 88, 96, 102, 108, 114, 117, 133, 142, 143, 151, 152, 158, 166, 179, 183, 190, 192, 212, 216, 217, 219, 229, 231] .

Thirty-four studies addressed secondary or co-infections [22, 24, 50, 51, 89, 91, 92, 96, 105, 106, 110, 127, 133, 143, 145, 151, 157, 158, 162, 163, 165, 166, 177, 182, 185, 189-191, 194, 199, 200, 212, 217, 219] . The majority of reported cases were bacterial urinary tract infection in kidney transplant recipients [89, 96, 151, 165, 166, 212] Of note, Nair et. al documented that 3 recipients, out of 10 kidney transplant patients, developed positive urine culture (Enterococcus, Klebsiella and E.coli) [166] and while Goss et.

al report a culture with Group B streptococcus [96] . Respiratory secondary bacterial infections due to epidermidis and two patients with Staphylococcus aureus [143] . Clostridium difficile colitis was reported in three patients [177, 185] .

Regarding viral secondary infection we six reports of Cytomegalovirus infection [50, 51, 143, 158, 177, 190] . Molaei et. al reports four patients having COVID-19 and CMV co-infection with a viremia of 412-592 IU/mL [158] , on the other hand, Pereira et. al also reports five patients with CMV with a median of 1469 (1326-8994) IU/mL [177] while Pierroti et. al reports 9 patients with CMV viremia [179] . Only one case of Influenza A co-infection was reported [200] . Two other patients had co-infections with HHV-6 and EBV [177] . There is also a report on a patient with a recent history of slight BK viremia that largely increased after COVID-19 infection [145] .

Fungal secondary infections were also reported. Candidemia was reported in 1 liver transplant recipient [106] and other solid organ transplant patients with Candida glabrata candidemia [177] and fungal infections with Aspergillus versicolor and severe cutaneous candidiasis [191] . Finally, Kates et. al.

reported a pneumonia due to cryptococcus species as well as a patient with Pneumocystis pneumonia [22] .

There are 62 studies documented about the duration of viral shedding and time to negativity of RT-PCR on NP specimens [1, 15, 24, 35, 36, 39, 45, 47, 55, 60, 61, 66, 67, 70, 72, 75, 80, 91, 92, 96-98, 105, 106, 110, 113, 115, 118-122, 125, 130, 134, 136-138, 140, 147, 148, 161-164, 170, 174, 176, 180, 182, 197, 198, 200, 207, 213, 218, 220, 221, 226, 229, 230, 232, 241] Majority of patients achieved negativity around 3 to 5 weeks from the initial positive result. The NP swab RT-PCR methods varied from study to study and the time from onset of symptoms to first positive RT-PCR result was not assessed. However, J o u r n a l P r e -p r o o f we identified that SOT recipients achieved RT-PCR negativity on day 5 at the earliest [170] and day 56 at the latest [182] in this systematic review. No studies were found documenting viral culture of SARS-CoV-2 among SOT recipients.

Also, 52 articles documented about rejection after COVID-19 [18, 22-24, 31, 40, 43, 50, 65, 69, 70, 81, 84, 88, 92, 98, 101, 103-105, 108, 114, 116, 118, 120, 123, 125, 130, 133-135, 143, 145, 154, 165, 171, 173, 175, 179, 183, 186, 191, 192, 199, 201, 205, 207, 210, 220, 224, 230, 231] [18, 22-24, 65, 81, 84, 92, 98, 101, 103-105, 108, 116, 118, 120, 123, 125, 130, 133-135, 143, 173, 175, 186, 191, 192, 199, 201, 210, 224, 230, 231] . During the follow up period, the pooled incidence of rejection was calculated only at 1.0% (95% CI, 0.2%-1.7%, FEM, I 2 0.0%) [22, 23, 65, 81, 88, 108, 114, 133, 135, 143, 179, 183, 192, 210, 231] .

Finally, we assessed all-cause mortality after COVID-19 in SOT recipients. We identified 37 articles and 18.6% died from any cause (95% CI, 14.8%-22.3%, REM, I 2 72.4%) during their follow-up period [18, 20, 22, 31, 55, 59, 60, 65, 70, 79, 81, 85, 88, 96, 102, 108, 114, 117, 133, 141-143, 151, 152, 156, 158, 166, 179, 189, 190, 192, 210, 212, 216, 219, 229, 231] 

We conducted the same analysis for the subset of kidney transplant recipients [16, 18, 20-24, 31, 32, 38, 43, 51, 55, 60, 65, 79, 81, 85, 88, 96, 100, 102, 114, 136, 142, 143, 149, 151, 152, 156, 158, 166, 179, 185, 189, 192, 210, 212, 228, 229, 231] . Fever, cough, and shortness of breath were seen in 70 

This is the first full systematic review and meta-analysis regarding COVID-19 in SOT recipients during the first wave of the pandemic in terms of symptoms, treatment strategy (including reduction in immunosuppression), and short-term outcomes. First, one fifth of this vulnerable population died after COVID-19 in a short term. Next, fever was common and reported in 70.2% but respiratory symptoms (cough and shortness of breath) were found in 63.8% and 49.1% respectively. Non-respiratory symptoms such as diarrhea were also seen in 30.4%. Also, we found that in the majority of SOT recipients, antimetabolites were either reduced or stopped completely.

In the general population, risk factors for severe COVID-19 infection have been well documented, such as hypertension, older age, and diabetes mellitus. Immunosuppressive medications have been thought to be a risk factor for severe illness from COVID-19 [6] . Even our meta-analysis showed a significantly higher admission rate (81.0%) as compared to the general population, which may not entirely reflect disease severity but rather the management strategy as employed by treating physicians who may prefer closer inpatient monitoring. Our meta-analysis showed incidence of lower respiratory tract infection (based on abnormal imaging), ICU admission rate and mortality of 79.7%, 29%, and 18.6% respectively, which are all comparable to the large published data in non-SOT, general population [242] . Even though T-cell immunity against respiratory viruses in SOT recipients is thought to be lower than the general population, viral clearance for SARS-CoV-2 in SOT recipients was around a median of 3-5 weeks, which again, is almost comparable to general population [242] .

Similarly, as compared to oncology patients, which were also recognized as immunocompromised and high risk for severe COVID-19, our data showed comparable outcomes especially for hospital admission rate and mortality [243] . Even though this meta-analysis shows high incidence of mortality in SOT recipients when compared with the general population [242] , it is important to note that these studies are not entirely comparable given the differences in associated comorbidities within the cohorts, such as incidence of diabetes or obesity. documented a mortality of around 40% [244] , which is significantly higher than SOT recipients.

In general, secondary infection was reported and found to be rare. In our study, some authors reported bacterial infection, especially urine culture positivity in kidney transplant recipients [89, 151, 165, 166, 212] . We cannot conclude if these infections occurred due to COVID-19 or were simply hospital acquired. Six reports of Cytomegalovirus infection were found in our study [50, 51, 143, 158, 177, 190] .

In general, Aspergillus co-infection was also reported, Rinaldi et. al reported twelve pulmonary aspergillosis [189] , Pereira et.al reported also a patient with aspergillus infection [177] , while other authors report a case of a lung transplant recipient with a positive bronchoalveolar lavage for Aspergillus fumigatus [163] and a case of Aspergillus versicolor [191] . Even though SOT recipients, especially lung transplant, are at highest risk for Aspergillosis, we found a relatively lower rate of Aspergillosis after COVID-19. This may be due to a short follow-up period or use of post-lung transplant anti-mold prophylaxis, even prior to COVID-19.

This systematic review and meta-analysis has several limitations. First, we found significant heterogeneity between studies. This may be in part due to a wide variety of different transplant types, immunosuppressive agents, and a lack of uniform treatment of COVID-19. Definition of certain clinical presentations, such as fever, also varied from study to study, giving rise to further heterogeneity. Even after factoring in heterogeneity into our analyses, we could not completely overcome it. Secondly, we could only perform analyses in the subset of kidney transplant recipients. Due to sample size limitations, we could not perform the same for other transplant types. Next, the follow-up period varied significantly from study to study and that prevented us from capturing certain outcomes, such as rate of rejection, allograft dysfunction, secondary infection, and even mortality. Finally, it is important to note that this systematic review and meta-analysis reflects our initial experience with this ever rapidly growing pandemic, and as treatment modalities and strategies evolve in the coming months, this is likely to J o u r n a l P r e -p r o o f Journal Pre-proof change. Moreover, differences in the available resources, epidemiology and demographics, from country to country, also play an important factor when it comes to the management of these highly immunosuppressed patients.

In conclusion, we performed a systematic review and meta-analysis of COVID-19 in SOT recipients regarding symptoms, treatment options, and outcomes. Based on this review and meta-analysis, we conclude that a higher admission rate was noted but overall outcome was similar to the general population. Further studies are still required to assess the long-term outcomes including allograft rejection, secondary infections and mortality in this highly immunocompromised patient population. [18, 20, 22, 31, 56, 59, 60, 65, 70, 79, 81, 85, 88, 96, 102, 108, 117, 133, 136, 141-143, 151, 152, 156, 158, 166, 179, 189, 190, 192, 210, 212, 216, 217, 219, 229, 231] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. Figure 2B : Pooled incidence of shortness of breath showing the absolute risk and 95% confidence intervals of each study (n=36) [18, 20, 22, 31, 55, 60, 65, 70, 79, 81, 85, 88, 96, 102, 108, 117, 133, 136, 142, 143, 151, 152, 156, 158, 166, 179, 189, 190, 192, 210, 212, 216, 217, 219, 229, 231] Abbreviations.

ES; Effect Size, CI; Confidence Interval, *=study period not defined. Figure 2C : Pooled incidence of cough showing the absolute risk and 95% confidence intervals of each study (n=38) [18, 20, 22, 31, 55, 59, 60, 65, 70, 79, 81, 85, 88, 96, 102, 108, 114, 117, 133, 136, 141, 143, 151, 152, 156, 158, 166, 179, 189, 190, 192, 210, 212, 216, 217, 219, 229, 231] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. Figure 2D : Pooled incidence of diarrhea showing the absolute risk and 95% confidence intervals of each study (n=36) [16, 18, 24, 31, 38, 40, 43, 51, 55, 65, 69, 79, 85, 96, 100, 117, 133, 136, 141, 142, 149, 151, 158, 162, 166, 179, 185, 189, 190, 192, 212, 216, 217, 219, 228, 231] . Abbreviations. ES; Effect Size, CI;

Confidence Interval, *=study period not defined. in solid organ transplant recipients and COVID-19, showing the absolute risk and 95% confidence intervals of each study (n=28) [22, 31, 59, 65, 79, 81, 85, 96, 102, 114, 117, 133, 143, 152, 156, 158, 166, 179, 189, 190, 192, 210, 212, 216, 217, 219, 229, 231] confidence intervals of each study (n=27) [18, 20-23, 55, 59, 79, 81, 108, 117, 133, 135, 143, 156, 166, 175, 189-192, 212, 216, 229, 231] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. Figure 4B : Pooled incidence of reduction in calcineurin inhibitor showing the absolute risk and 95% confidence intervals of each study (n=31) [16, 18, 20, 21, 23, 24, 38, 51, 55, 79, 81, 117, 128, 133, 143, 151, 166, 175, 189, 191, 212, 216, 228, 229, 231] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. Figure 4C : Pooled incidence of reduction in steroid showing the absolute risk and 95% confidence intervals of each study (n=17) [18, 21, 23, 51, 81, 100, 128, 151, 166, 191, 192, 212, 216, 229] .

Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. [18, 20, 22, 31, 55, 59, 60, 65, 70, 81, 102, 108, 117, 133, 143, 151, 166, 175, 189-192, 210, 212, 216, 219] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. [18, 20, 22, 55, 59, 60, 65, 70, 102, 166, 189, 190, 210, 216, 219] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. [18, 20, 22, 55, 60, 70, 79, 85, 88, 117, 133, 136, 189, 192, 210] . [20, 24, 31, 55, 60, 70, 108, 143, 151, 162, 175, 189, 210, 212] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined. Figure E : Pooled incidence of steroids showing the absolute risk and 95% confidence intervals of each study (n=19) [18, 20, 22, 55, 60, 70, 81, 108, 117, 133, 142, 143, 156, 175, 189, 192, 210, 231] . Abbreviations. ES; Effect Size, CI; Confidence Interval, *=study period not defined.

J o u r n a l P r e -p r o o f 

Included Eligibility 

97.1%)

IL-6 antagonists were used in 17.3% (95% CI, 10.0%-24.6%, REM, I 2 88.1%), protease inhibitors in 37.7% (95% CI, 23.2%-52.2%, REM, I 2 89.1%), with high dose steroids in 44.4% (95% CI, 27.3%

All-cause mortality in the subset of kidney

Non-kidney solid organ transplant recipients: References

A Novel Coronavirus from Patients with Pneumonia in China

Coronavirus disease (COVID-19) -Situation Report in, World Health Organization

A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients

T-cell responses following Natural Influenza Infection or Vaccination in Solid

Coronavirus Disease 2019 -People of Any Age with Underlying Medical Conditions, in

COVID-19: immunopathology and its implications for therapy

Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?

Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis

Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

MERS transmission and risk factors: a systematic review

Rethinking high-risk groups in COVID-19

SARS-CoV2 and immunosuppression: A double-edged sword

Hlh Across Speciality Collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

Clinical Characteristics and Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Case-Control Study

COVID-19 in kidney transplant recipients

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

s. group, COVID-19 and Kidney Transplantation: Results from the TANGO International Transplant Consortium

Group, Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients

Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study

COVID-19 in solid organ transplant recipients: A single-center case series from Spain

Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement

COVID-19 Literature Searches

MEDLINE® 2020 Database Guide

COVID-19 and kidney transplant recipients

Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients

Telemedicine in the Care of Kidney Transplant Recipients With Coronavirus Disease 2019: Case Reports

COVID-19 in Renal Transplant Patient Presenting With Active Typical Symptoms and Resolved Atypical Symptoms

A Kidney Transplant Recipient With Coronavirus Disease 2019: Utility of a Prognostication Score

Pneumatosis intestinalis in a patient with COVID-19

COVID-19 in a lung transplant recipient

Covid-19 and Kidney Transplantation

Coronavirus Disease (COVID-19) in Kidney and Liver Transplant Patients: A Single-Center Experience

Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience

Neutropenic fever in COVID-19 in kidney transplant patient

A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia

Coronavirus Disease-19: Disease Severity and Outcomes of Solid Organ Transplant Recipients: Different Spectrum of Disease in Different Populations?

Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient

Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy

Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation

Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders

Clinical Profiles in Renal Patients with COVID-19

Case report: A kidney transplant patient with mild COVID-19

COVID-19 in lung transplant recipients: A single center case series from

COVID-19 infection in kidney transplant recipients

Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease

COVID-19 in an international European liver transplant recipient cohort

COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry, The Lancet

-depth virological assessment of kidney transplant recipients with COVID-19

Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy, The Lancet

A catabolic state in a kidney transplant recipient with COVID-19

Attenuated early inflammatory response in solid organ recipients with COVID-19

Kidney transplant patients with SARS-CoV-2 infection: the brescia renal COVID task force experience

Does interval time between liver transplant and COVID-19 infection make the difference?

Mild COVID-19 in a pediatric renal transplant recipient

Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report

Outpatient COVID-19 surveillance testing in orthotopic heart transplant recipients

Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy, Microorganisms

A familial cluster, including a kidney transplant recipient

Coronavirus disease 2019 in renal transplant recipients: report of two cases

Coronavirus Disease 2019 (COVID-19) in a Renal Transplant Patient

Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients

University Kidney Transplant, Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York

COVID-19 pneumonia in lung transplant recipients: report of two cases

COVID-19 in elderly kidney transplant recipients

Uneventful case of COVID-19 in a kidney transplant recipient

COVID-19 in a young liver transplant recipient: caution for drug-drug interactions

Pneumocystis jirevocii and SARS-CoV-2 Co-Infection: A Common Feature in Transplant Recipients?, Vaccines (Basel)

Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection

Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation

COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul

Discordant courses of COVID-19 in a cohabiting couple of lung transplant recipients

COVID-19 Infection in Kidney Transplant Recipients: A Single-Center Case Series of 22 Cases From Belgium

Fatal SARS-CoV-2 infection in a renal transplant recipient

Lessons for the clinical nephrologist: recurrence of nephrotic syndrome induced by SARS-CoV-2

COVID-19 infection in pancreas transplant recipients

COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes

Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19

Sars-Cov-2 Foch Hospital study, COVID-19 in lung-transplanted and cystic fibrosis patients: Be careful

Initial Report From a Swedish High-Volume Transplant Center After The First Wave of The COVID-19 Pandemic

COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine

Treatment of Immunocompromised COVID-19 patients with Convalescent Plasma

Persistently positive severe acute respiratory syndrome coronavirus 2 (SARS-COV2) nasopharyngeal PCR in a kidney transplant recipient

COVID-19 and liver transplantation: Lessons learned from three reported cases

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab

COVID-19 in solid organ transplant recipients

COVID-19 in a lung transplant recipient: Exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression

The Pediatric Solid Organ Transplant Experience with COVID-19: An Initial Multi-Center, Multi-Organ Case Series

Favorable Outcome of COVID-19 Pneumonia in a Kidney Transplant Recipient Treated with Tocilizumab

Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report

Controversies Regarding Shielding and Susceptibility to COVID-19 Disease in Liver transplant Recipients in the United Kingdom

Evidence of potent humoral immune activity in COVID19-infected kidney transplant recipients

A case of an Infant with SARS-CoV-2 hepatitis early after liver transplantation

Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options

COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient

COVID-19 in posttransplant patients-report of 2 cases

Fatal outcome in a liver transplant recipient with COVID-19

Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease

A case series of Novel-Coronavirus infection in heart transplantation from two centers in the pandemic area in the North of Italy

COVID-19 Leading to Acute Encephalopathy in a Heart Transplant Patient‖

Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with serve clinical manifestation and complex complications

Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression

Collapsing Glomerulopathy Associated with COVID-19 Infection in a Heart Transplant Recipient

Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States

Outcomes of COVID-19-positive kidney transplant recipients: A single-center experience

Early COVID-19 infection after lung transplantation

Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection

Coronavirus Disease-2019 in Heart Transplant Recipients in Southeastern Michigan: A Case Series

Two distinct cases with COVID-19 in kidney transplant recipients

A Case Report of Oligosymptomatic Kidney Transplant Patients with COVID-19: Do They Pose a Risk to Other Recipients?

SARS-CoV-2 infection in two patients following recent lung transplantation

COVID-19 infection in solid organ transplant recipients: A single-center experience with patients immediately after transplantation

COVID-19 in an HIV-positive Kidney Transplant Recipient

COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation

Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease

Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab

COVID-19&#x2013;Related Collapsing Glomerulopathy in a Kidney Transplant Recipient

Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19

COVID-19 in Liver Transplant Recipients: An Initial Experience from the U

Varying Presentations of COVID-19 in Young Heart Transplant Recipients: A Case Series

First cases of COVID-19 in heart transplantation from China

SARS-CoV-2 and viral sepsis: observations and hypotheses

Severe acute respiratory syndrome coronavirus 2 infection in renal transplant recipients: A case report

COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes

Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient

Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients

Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center

Case of "relapsing" COVID-19 in a kidney transplant recipient

COVID-19 pneumonia in kidney transplant recipients-Where we are?

A Report of 85 Cases of COVID-19 and Abdominal Transplantation From a Single Center: What Are the Associated Factors With Death Among Organ Transplantation Patients

Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia

Clinical Characteristics, Hospitalization and Mortality Rates of COVID-19 Among Liver Transplant Patients in the United States: A Multi

In response to the letter of Montagud-Marrahi et al

SARS-CoV-2 infection in kidney transplant recipients: experience of the italian marche region

First case of COVID-19 in a kidney transplant recipient treated with belatacept

Resurgence of BK virus following Covid-19 in kidney transplant recipients

COVID-19 Infection in Early Post-Operative Period after Liver Transplantation

A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant

Heart transplant recipient patient with COVID-19 treated with tocilizumab

Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge

Spanish Pediatric Nephrology, SARS-CoV-2 infection in Spanish children with chronic kidney pathologies

Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab

Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics

Vall d'Hebron, COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management

Coronavirus Disease 2019 in an Orthotopic Liver Transplant Recipient Living with Human Immunodeficiency Virus

Outcomes of Renal Transplant Recipients With SARS-CoV-2 Infection in the Eye of the Storm: A Comparative Study With Waitlisted Patients

Renal Transplant Recipient with Concurrent COVID-19 and Stenotrophomonas maltophilia Pneumonia Treated with Trimethoprim/Sulfamethoxazole Leading to Acute Kidney Injury: A Therapeutic Dilemma

Iranian kidney transplant recipients with COVID-19 infection: Clinical outcomes and cytomegalovirus coinfection

Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States

Clinical characteristics and outcome of COVID-19 pneumonia in kidney transplant recipients in Razi hospital

Child with liver transplant recovers from COVID-19 infection. A case report

Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2

Lung Transplant Recipients: A Case Series From

Recovery from COVID-19 following Hepatitis C, Human Immunodeficiency Virus Infection and Liver Transplantation

Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy

COVID-19 in kidney transplant recipients

Novel Corona Virus 2019 pneumonia in a kidney transplant recipient

COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature

Liver transplantation and COVID-19: a case report and cross comparison between two identical twins with COVID-19

Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report

Collapsing Glomerulopathy Affecting Native and Transplant Kidneys in Individuals with COVID-19

De Novo Focal and Segmental Glomerulosclerosis After COVID-19 in a Patient With a Transplanted Kidney From a Donor With a High-risk APOL1 Variant

Successful implementation of preventive measures leads to low relevance of SARS-CoV-2 in liver transplant patients: Observations from a German outpatient department

Novel coronavirus (SARS-CoV-2) infection in a patient with multivisceral transplant

Spanish Society of Nephrology, COVID-19-related Mortality During the First 60 Days After Kidney Transplantation

Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy

Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study

COVID-19 among kidney transplant recipients requiring hospitalization: preliminary data and outcomes from a single-center in Brazil

A case of COVID-19 immediately after liver transplantation: Not only bad news

Early Description of Coronavirus

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

Liver Injury in Liver Transplant Recipients with Coronavirus Disease

Immunosuppression in a lung transplant recipient with COVID-19? Lessons from an early case

Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center

Detection of SARS-CoV-2 by bronchoscopy after negative nasopharyngeal testing: Stay vigilant for COVID-19

COVID-19 pneumonia presenting as a single pulmonary nodule in a kidney transplant recipient: A case report and literature review

Bilateral Acute Cardioembolic Limb Ischemia After Coronavirus Disease 2019 Pneumonia in a Lung Transplant Recipient: A Case Report

COVID-19 in solid organ transplant recipients: No difference in survival compared to general population

COVID-19 among heart transplant recipients in Germany: a multicenter survey

COVID-19 in solid organ transplant recipients: dynamics of disease progression and inflammatory markers in ICU and non-ICU admitted patients

Sagastagoitia Fornie, A.I. Sanchez-Fructuoso, Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?

COVID-19 in a pediatric heart transplant recipient: Emergence of donor-specific antibodies

A family cluster of diagnosed coronavirus disease 2019 (COVID-19) kidney transplant recipient in Thailand

Inmunoglobulinas por vía intravenosa: una alternativa terapéutica a tener en cuenta en el paciente trasplantado renal con COVID-19

SARS Cov-2 infection in a renal-transplanted patient: A case report

Incidental COVID-19 in a Heart-Kidney Transplant Recipient with Malnutrition and Recurrent Infections: Implications for the SARS-CoV-2 Immune Response

COVID-19 in recent kidney transplant recipients

Challenges in Heart Transplantation during COVID-19: A Single Center Experience

Clinical characteristics of four cancer patients with SARS-CoV-2 infection in

Heart Retransplantation Following COVID-19 Illness in a Heart Transplant Recipient

Donor-derived cell-free DNA in a heart transplant patient with COVID-19

COVID-19 pneumonia in a dual heartkidney recipient

Fatal Outcome in a Kidney-Pancreas Transplant Recipient With COVID-19

Coronavirus Disease 2019 in Immunocompromised Organ Transplant Recipients: A Case Report and Review of the Literature

Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia

Insights in the approach of long-term liver transplant recipients with COVID-19

A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

SARS-CoV-2 Infection in Hospitalized Patients with Kidney Disease

Tocilizumab use in Kidney Transplant Patients with COVID-19

Swiss Transplant Cohort, First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report

COVID-19 infection after recent heart transplantation: a case report

Care of Asymptomatic SARS-CoV-2 positive Kidney Transplant Recipients

COVID-19 in lung transplant patients: a case series

Low prevalence and disease severity of COVID-19 in post liver transplant recipients -a single centre experience

Severe COVID-19 After Recent Heart Transplantation Complicated by Allograft Dysfunction

Liver Transplant Recipients Infected with SARS-CoV-2 in the Early Postoperative Period: Lessons from a Single Center in the Epicenter of the Pandemic

Influence of immunosuppression on seroconversion against SARS-CoV-2 in two kidney transplant recipients

COVID-19 in a Kidney Transplant Patient

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Determining risk factors for mortality in liver transplant patients with COVID-19, The lancet

Allograft infiltration and meningoencephalitis by SARS-CoV-2 in a pancreas-kidney transplant recipient

Failed antibody response in a renal transplant recipient with SARS-CoV-2 infected

Renal Infarct in a COVID-19 Positive Kidney-Pancreas Transplant Recipient

Minimal Change Disease With Nephrotic Syndrome Associated With Coronavirus Disease 2019 After Apolipoprotein L1 Risk Variant Kidney Transplant: A Case Report

Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center

Identification of Kidney Transplant Recipients with Coronavirus Disease

Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients

Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in

Slow Recovery from Critical Coronavirus Disease 2019 Pneumonia in an Immunosuppressed Renal Transplant Recipient with Early Acute Cardiorenal Syndrome

Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report

First report of novel coronavirus infection following abdominal organ transplantation in North America during the COVID-19 pandemic

Different clinical presentations of two renal transplant recipients with coronavirus disease 2019: a case report

A Proposed Strategy for Management of Immunosuppression in Heart Transplant Patients with COVID-19

Follow-up and Management of Kidney Transplant Recipients During the COVID-19 Lockdown: The Experience of an Italian Transplant Center, Including Two Cases of COVID-19 Pneumonia

Low Rate of COVID-19 pneumonia in Kidney Transplant Recipients -A Battle Between Infection and Immune Response?

SARS-CoV-2 infection in kidney transplant recipients: Early report of five cases

An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants

Belatacept, kidney transplantation and COVID-19: Successful management of the first reported case within the United Kingdom

China Medical Treatment Expert Group for, Clinical Characteristics of Coronavirus Disease 2019 in China

COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis

COVID-19 outcomes in patients with hematologic disease

transplantation'/de OR 'allograft'/exp OR 'allotransplantation'/de OR 'autograft'/exp OR 'autotransplantation'/de OR 'haploidentical transplantation'/de OR 'heterotopic transplantation'/de OR 'isograft'/de OR 'isotransplantation'/de OR 'organ transplantation'/exp OR 'orthotopic transplantation'/de OR 'retransplantation'/de OR 'graft recipient'/de OR 'organ donor'/exp OR 'solid organ':ab,ti,kw OR 'solid organs':ab,ti,kw OR (((organ OR graft) NEXT/2 (donor* OR recipient*)):ab,ti,kw)) NOT ((rat:ti OR rats:ti OR mouse:ti OR mice:ti OR swine:ti OR porcine:ti OR murine:ti OR sheep:ti OR lambs:ti OR pigs:ti OR piglets:ti OR rabbit:ti OR rabbits:ti OR cat:ti OR cats:ti OR dog:ti OR dogs:ti OR cattle:ti OR bovine:ti OR monkey:ti OR monkeys:ti OR trout:ti OR marmoset$:ti) AND 'animal experiment'/de OR

The authors would like to thank Tara Brigham, MLIS, from the Mayo Clinic Libraries in Jacksonville, FL, for peer review of the Medline database search strategy.

The authors declare no-funding for this study.

and Daily Run June 11, 2020, updated July 13, 2020, August 20, 2020, and October 8, 2020. 1 [orcid.org/0000-0001-6744-3517] 2[SARS-Cov-2 and Covid-19 terms] 3 exp Coronavirus/ or exp Coronavirus Infections/ 4 (("Corona virinae" or "corona virus" or Coronavirinae or coronavirus or COVID or nCoV) adj4 novel or new or neue or nuevo or nouveau)).rx,ti,ab,hw,kw. 5 (("Corona virinae" or "corona virus" or Coronavirinae or coronavirus or COVID or nCoV) and (W China or Chinese)).rx,ti,ab,hw,kw. 6 ("Corona virinae19" or "Corona virinae2019" or "corona virus19" or "corona virus2019" or C Coronavirinae2019 or coronavirus19 or coronavirus2019 or COVID19 or COVID2019 or nCOV or "SARS Corona virus 2" or "SARS Coronavirus 2" or "SARS-COV-2" or "Severe Acute Resp Corona Virus 2" or "Severe Acute Respiratory Syndrome Coronavirus 2").rx,ti,ab,hw,kw. J o u r n a l P r e -p r o o f Journal Pre-proof or Coronavirinae19 or Coronavirinae2019 or coronavirus19 or coronavirus201 9 or COVID19 or COVID2019 or nCOV19 or nCOV2019 or "SARS Corona virus 2" or "SARS Coronavirus 2" or "SARS-COV-2" or "Severe Acute Respiratory Syndrome Corona Virus 2" or "Severe Acut e Respiratory Syndrome Coronavirus 2") # 1 TS=(("Corona virinae" or "corona virus" or Coronavirinae or coronavirus or COVID or nCoV ) AND (Wuhan or Hubei or China or Chinese) )